Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc.
Dr. Lambert joined ImmunoGen Inc. in 1987 and played an important role in translating the technology of ImmunoGen into antibody-drug conjugate (ADC) clinical development programs. These efforts ultimately led to Kadcyla®, one of the first ADCs that was approved by the FDA as well as many additional ADC programs that continue to be developed by ImmunoGen and its partners.
He is the author/co-author of more than 120 peer-reviewed scientific publications. In 2016, Dr. Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Prior to joining ImmunoGen, he served as Assistant Professor of Pathology at the Dana-Farber Cancer Institute of the Harvard Medical School. Dr. Lambert holds a PhD in Biochemistry from University of Cambridge in England and completed his postdoctoral work at the University of California at Davis and Glasgow University in Scotland.
“We are pleased to expand our Scientific Advisory Board with the addition of Dr. Lambert,” said Prof. Floris van Delft, CSO of Synaffix, “his extensive and highly relevant experience in the ADC field will be invaluable as our technology is embraced by a growing list of collaborators with multiple ADC programs advancing into the clinic.”
Synaffix is creating technologies that aid the development of ADCs and other conjugates. Their proprietary technologies include:
- GlycoConnect - site-specific antibody conjugation technology
- HydraSpace - ADC-enhancing spacer technology
- toxSYN - ADC Payloads
- Best-in-Class Metal-Free Click Chemistry